- Home
- ESPR vs DOMO Comparison
ESPR vs DOMO Comparison
Compare ESPR & DOMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- DOMO
- Stock Information
- Founded
- ESPR 2008
- DOMO 2010
- Country
- ESPR United States
- DOMO United States
- Employees
- ESPR N/A
- DOMO N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- DOMO Computer Software: Prepackaged Software
- Sector
- ESPR Health Care
- DOMO Technology
- Exchange
- ESPR Nasdaq
- DOMO Nasdaq
- Market Cap
- ESPR 305.0M
- DOMO 308.9M
- IPO Year
- ESPR 2013
- DOMO 2018
- Fundamental
- Price
- ESPR $1.50
- DOMO $8.21
- Analyst Decision
- ESPR Buy
- DOMO Hold
- Analyst Count
- ESPR 7
- DOMO 6
- Target Price
- ESPR $6.36
- DOMO $10.42
- AVG Volume (30 Days)
- ESPR 3.5M
- DOMO 343.7K
- Earning Date
- ESPR 03-04-2025
- DOMO 03-06-2025
- Dividend Yield
- ESPR N/A
- DOMO N/A
- EPS Growth
- ESPR N/A
- DOMO N/A
- EPS
- ESPR N/A
- DOMO N/A
- Revenue
- ESPR $332,314,000.00
- DOMO $317,044,000.00
- Revenue This Year
- ESPR $5.51
- DOMO $0.86
- Revenue Next Year
- ESPR $1.42
- DOMO $1.94
- P/E Ratio
- ESPR N/A
- DOMO N/A
- Revenue Growth
- ESPR 185.66
- DOMO N/A
- 52 Week Low
- ESPR $1.47
- DOMO $6.11
- 52 Week High
- ESPR $3.94
- DOMO $10.15
- Technical
- Relative Strength Index (RSI)
- ESPR 34.95
- DOMO 52.28
- Support Level
- ESPR $1.57
- DOMO $7.00
- Resistance Level
- ESPR $1.86
- DOMO $8.65
- Average True Range (ATR)
- ESPR 0.13
- DOMO 0.45
- MACD
- ESPR -0.01
- DOMO 0.04
- Stochastic Oscillator
- ESPR 7.69
- DOMO 73.56
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About DOMO Domo Inc. Class B
Domo Inc provides a cloud-based platform that digitally connects all the data, systems and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.